Payment overview · 2025
General Payments
$59.24
3 reported records · 3 companies
Healthcare provider profile · identity verified
Thomas Waldon Staton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · METROPOLIS, IL · NPI 1306825500
Verified facts
What the public records show
CMS Open Payments records show Thomas Waldon Staton, M.D. received $59.24 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.87 | 38.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.71 | 36.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.66 | 24.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.24 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 773 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 117 |
| Lisinopril | Lisinopril | 552 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 378 | 91 |
| Gabapentin | Gabapentin | 353 | 65 |
| Losartan Potassium | Losartan Potassium | 339 | 90 |
| Furosemide | Furosemide | 301 | 45 |
| Carvedilol | Carvedilol | 290 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 290 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 281 | 81 |
| Omeprazole | Omeprazole | 279 | 71 |
| Potassium Chloride | Potassium Chloride | 274 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 264 | 68 |
| Metformin Hcl | Metformin Hcl | 232 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 51 |
| Eliquis | Apixaban | 184 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 38 |
| Famotidine | Famotidine | 150 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 25 |
| Buspirone Hcl | Buspirone Hcl | 133 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 42 |
| Lovastatin | Lovastatin | 131 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 41 |
| Nifedipine Er | Nifedipine | 123 | 31 |
| Ozempic | Semaglutide | 120 | 24 |
| Tramadol Hcl | Tramadol Hcl | 120 | 25 |
| Synthroid | Levothyroxine Sodium | 118 | 22 |
| Jardiance | Empagliflozin | 115 | 18 |
| Simvastatin | Simvastatin | 111 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 33 |
| Lorazepam | Lorazepam | 110 | 28 |
| Trazodone Hcl | Trazodone Hcl | 110 | 25 |
| Memantine Hcl | Memantine Hcl | 108 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 29 |
| Clonidine Hcl | Clonidine Hcl | 103 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 21 |
| Allopurinol | Allopurinol | 94 | 23 |
| Alprazolam | Alprazolam | 94 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 21 |
| Azithromycin | Azithromycin | 91 | 83 |
| Montelukast Sodium | Montelukast Sodium | 91 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 15 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 74 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 69 | 12 |
| Warfarin Sodium | Warfarin Sodium | 68 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Trulicity | Dulaglutide | 62 | 11 |
| Meloxicam | Meloxicam | 61 | 19 |
| Atenolol | Atenolol | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 21 |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Spironolactone | Spironolactone | 55 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Mounjaro | Tirzepatide | 49 | 11 |
| Prednisone | Prednisone | 48 | 40 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 30 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 13 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.24 · 3 records | Dexcom, Inc. | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, JARDIANCE, PREVNAR 20 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error